14-day Quadruple Therapy Versus Triple Therapy in HP Eradication

• Status: Completed
• Trial end date: 2020-03-05
• Target enrollment: 0
• Participant gender: All

Summary

In this prospective randomized-controlled study, treatment-naive H. pylori-infected patients are randomized to receive either standard triple therapy or sequential therapy. The aim is to compare the efficacy of concomitant quadruple therapy with standard triple therapy as a first line treatment for H. pylori infection in Tunisian patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: mohamed bouchoucha
• Treatments: Metronidazole

Criteria

Inclusion Criteria:

• patients aged between 18 and 65, with documented Hp infection.

Exclusion Criteria: are excluded patients:

• With Cirrhosis.

• With Renal failure (serum creatinine> 120 µmol / L).

• Having complicated peptic ulcer (stenosis or hemorrhage or perforation) in an acute phase.

• Having severe psychiatric disorders.

• Having had gastric surgery in their history.

• Having already received an HP eradication treatment.

• Having received an antibiotic within the last two weeks.

• Who are allergic to one of the antibiotics used in the anti-Hp cure.

• Who are drug addicted.